Hospital
Regents of the Univ of California
Regents of the Univ of California was paid $11.54M by Medicaid between Jan 2018 and Dec 2024, across 215 billing codes. Its largest line is 0450, Emergency room services — 20% of everything it billed.
33Billing provider infoREGENTS OF THE UNIV OF CALIFORNIA
SANTA MONICA, CA 90404
SANTA MONICA, CA 90404
33aNPI1427055839assigned 06/30/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.54M
24GClaims585,325
24DCodes billed215
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#165 of 410
Median peer was paid$6.90M
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 95,815 | $1.67M | |
| 2019 | 81,678 | $1.54M | |
| 2020 | 63,223 | $1.16M | |
| 2021 | 69,770 | $1.39M | |
| 2022 | 80,666 | $1.74M | |
| 2023 | 100,598 | $2.27M | |
| 2024incomplete | 93,575 | $1.77M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 20% | 56,698 | 47,983 | $2.34M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.1% | 3,803 | 3,567 | $592K |
| 0762 | 4.7% | 309 | 124 | $545K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.5% | 12,560 | 11,268 | $518K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 4,182 | 3,961 | $392K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.3% | 5,049 | 4,530 | $381K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.9% | 3,396 | 3,143 | $333K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.5% | 8,704 | 7,465 | $291K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.3% | 11,696 | 10,585 | $261K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.2% | 9,376 | 8,420 | $252K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.0% | 8,729 | 7,684 | $236K |
| J3490 | Unclassified drugs | 1.9% | 17,248 | 9,618 | $221K |
203 more codes
| 80048 | Basic metabolic panel (calcium, ionized) | 1.7% | 27,311 | $202K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 3,374 | $172K |
| 99283 | Emergency room visit (moderate) | 1.5% | 1,928 | $172K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 3,595 | $169K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 1,558 | $166K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.4% | 3,011 | $156K |
| 0710 | 1.3% | 1,448 | $151K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 28,076 | $146K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.1% | 786 | $131K |
| Z7502 | 1.1% | 3,326 | $122K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.0% | 141 | $118K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.0% | 2,692 | $118K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,470 | $115K |
| 99199 | Unlisted special service, procedure or report | <1% | 2,720 | $102K |
| 99285 | Emergency room visit (most serious) | <1% | 341 | $96K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 9,565 | $90K |
| 83880 | <1% | 4,511 | $85K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,774 | $83K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,848 | $81K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,854 | $81K |
| 87631 | <1% | 1,991 | $79K | |
| 84484 | <1% | 9,756 | $75K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,764 | $74K |
| 83690 | <1% | 13,707 | $73K | |
| 93971 | <1% | 1,035 | $71K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,994 | $61K |
| 80076 | <1% | 8,079 | $60K | |
| 0250 | <1% | 27,627 | $60K | |
| 80053 | Comprehensive metabolic panel | <1% | 4,880 | $58K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,558 | $56K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,054 | $55K |
| 85610 | <1% | 15,258 | $50K | |
| 73630 | <1% | 2,136 | $50K | |
| 82150 | <1% | 9,643 | $47K | |
| 76830 | Ultrasound, transvaginal | <1% | 843 | $47K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,017 | $45K |
| 73610 | <1% | 2,016 | $44K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,112 | $44K |
| 85730 | <1% | 8,757 | $42K | |
| 0370 | <1% | 745 | $41K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,782 | $38K |
| 73562 | <1% | 2,098 | $37K | |
| 73030 | <1% | 1,998 | $36K | |
| 87040 | <1% | 3,149 | $36K | |
| 73502 | <1% | 1,517 | $36K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,118 | $34K |
| 81001 | <1% | 12,966 | $33K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 586 | $32K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,381 | $31K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,361 | $31K |
| 82550 | <1% | 6,501 | $29K | |
| 73130 | <1% | 1,480 | $29K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,628 | $29K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,808 | $28K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,575 | $28K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 216 | $27K |
| 0949 | <1% | 686 | $26K | |
| 81025 | <1% | 5,467 | $24K | |
| 72100 | <1% | 1,053 | $24K | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 1,432 | $21K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 411 | $21K |
| 86900 | <1% | 2,070 | $21K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,976 | $21K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,534 | $20K |
| 73110 | <1% | 1,077 | $20K | |
| 84460 | <1% | 5,840 | $19K | |
| 84450 | <1% | 5,805 | $19K | |
| 73564 | <1% | 1,013 | $19K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,888 | $19K |
| 83605 | <1% | 2,182 | $19K | |
| 84075 | <1% | 5,790 | $18K | |
| 96376 | <1% | 1,156 | $18K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 25 | $18K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 247 | $18K |
| 82040 | <1% | 5,806 | $18K | |
| 73560 | <1% | 918 | $17K | |
| 85027 | <1% | 3,763 | $17K | |
| 97161 | <1% | 596 | $16K | |
| 86850 | <1% | 1,957 | $16K | |
| 83735 | <1% | 3,288 | $15K | |
| 73590 | <1% | 538 | $15K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,453 | $15K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,502 | $15K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,353 | $14K |
| 82248 | <1% | 4,281 | $14K | |
| 85379 | <1% | 1,646 | $14K | |
| 84703 | <1% | 2,615 | $14K | |
| 71250 | <1% | 133 | $14K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 139 | $14K |
| 99000 | <1% | 4,623 | $13K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 812 | $13K |
| 93970 | <1% | 150 | $13K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 68 | $13K |
| 86140 | <1% | 2,317 | $12K | |
| 86901 | <1% | 2,359 | $11K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 92 | $11K |
| 73552 | <1% | 309 | $10K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 784 | $10K |
| 87088 | <1% | 2,237 | $10K | |
| 87186 | <1% | 1,544 | $10K | |
| 87077 | <1% | 1,995 | $9K | |
| 94761 | <1% | 1,280 | $9K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 259 | $9K |
| 81002 | <1% | 4,525 | $9K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 439 | $9K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,985 | $8K |
| 87070 | <1% | 988 | $8K | |
| 82077 | <1% | 1,108 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,438 | $8K |
| 84702 | <1% | 783 | $8K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,893 | $8K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,290 | $8K |
| 80061 | Lipid panel | <1% | 1,030 | $7K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,271 | $7K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,286 | $7K |
| 70486 | <1% | 43 | $7K | |
| 84100 | <1% | 2,060 | $6K | |
| 0270 | <1% | 3,742 | $6K | |
| 80143 | <1% | 722 | $6K | |
| 80179 | <1% | 692 | $6K | |
| 82247 | <1% | 1,880 | $5K | |
| 90715 | <1% | 242 | $5K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 75 | $5K |
| 85652 | <1% | 1,874 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 228 | $5K |
| 82962 | <1% | 1,762 | $4K | |
| 77080 | <1% | 253 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 254 | $4K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 826 | $4K |
| 74018 | <1% | 177 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 70 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 68 | $3K |
| 73523 | <1% | 44 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 67 | $2K |
| 82553 | <1% | 245 | $2K | |
| G0378 | Hospital observation service, per hour | <1% | 19 | $2K |
| 70496 | <1% | 12 | $2K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 450 | $2K |
| 87205 | <1% | 485 | $2K | |
| 99221 | <1% | 55 | $2K | |
| 96367 | <1% | 53 | $2K | |
| 0258 | <1% | 1,389 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 301 | $2K |
| 0301 | <1% | 70 | $1K | |
| 83550 | <1% | 269 | $1K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 343 | $1K |
| 82728 | <1% | 172 | $1K | |
| 74183 | <1% | 12 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 358 | $1K |
| 0761 | <1% | 251 | $1K | |
| 82570 | <1% | 413 | $1K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 134 | $1K |
| 83540 | <1% | 275 | $1K | |
| 87340 | <1% | 102 | $1K | |
| 73140 | <1% | 88 | $1K | |
| Z7610 | <1% | 142 | $974.95 | |
| 94644 | <1% | 68 | $961.12 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 73 | $943.57 |
| 0324 | <1% | 76 | $858.68 | |
| 82803 | <1% | 83 | $846.28 | |
| 86803 | <1% | 59 | $822.37 | |
| 73090 | <1% | 46 | $749.88 | |
| 99152 | <1% | 40 | $743.05 | |
| 72040 | <1% | 33 | $737.13 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,627 | $721.33 |
| 87081 | <1% | 161 | $715.58 | |
| 73070 | <1% | 44 | $713.92 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 125 | $679.04 |
| 82746 | <1% | 81 | $648.99 | |
| 73080 | <1% | 42 | $618.34 | |
| 71010 | <1% | 31 | $605.59 | |
| 82105 | <1% | 24 | $593.22 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 53 | $549.45 |
| 72170 | <1% | 14 | $520.27 | |
| 82607 | <1% | 95 | $517.43 | |
| 86592 | <1% | 134 | $513.84 | |
| A4649 | Surgical supply; miscellaneous | <1% | 3,123 | $509.27 |
| 97116 | <1% | 67 | $434.68 | |
| 84145 | <1% | 37 | $434.62 | |
| 70498 | <1% | 13 | $425.87 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 16 | $410.04 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 42 | $354.78 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 53 | $297.84 |
| 84156 | <1% | 98 | $273.77 | |
| 71100 | <1% | 12 | $253.52 | |
| 73060 | <1% | 13 | $248.01 | |
| 84439 | <1% | 58 | $242.28 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 71 | $237.32 |
| 0636 | <1% | 266 | $212.51 | |
| 10060 | <1% | 13 | $143.37 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 58 | $136.04 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 15 | $124.32 |
| 0305 | <1% | 12 | $77.60 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 12 | $76.53 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 337 | $54.93 |
| 82565 | <1% | 14 | $51.24 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 481 | $47.60 |
| 0637 | <1% | 43 | $45.78 | |
| 84550 | <1% | 12 | $37.78 | |
| 83615 | <1% | 15 | $33.70 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 62 | $24.04 |
| 0510 | 0% | 23 | $0.00 | |
| 0272 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWALLACE, TAMMY (CFO)
| Provider | Location | Paid |
|---|---|---|
| Regents Univ of Calif Los Angeles | Los Angeles, CA | $41.47M |
| Regents of the University of | Panorama City, CA | $2.36M |
| Regents Univ of Calif Los Angeles | West Hills, CA | $360K |
| Regents Univ of Calif Los Angeles | Los Angeles, CA | $19K |
| DR Tammy Wallace LLC | Ozark, AL | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.